X4 Pharmaceuticals Raises $65 Million: Tune in to the Phase 3 Clinical Data Webinar Today at 4PM ET!

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) has just announced a major investment victory for its future! The leading discovery and development company for novel small molecule therapeutics to benefit people with rare diseases of the immune system has entered into a private investment in public equity (PIPE) financing agreement to sell 42,784,203 shares of common stock (or pre-funded warrants in lieu thereof).

This is expected to bring in an impressive $65 million in gross proceeds, before deducting fees to the placement agents and other estimated offering expenses payable by the Company. The closing of this major financing is expected to take place on or about May 18, 2023, subject to customary closing conditions.

X4 Pharmaceuticals is proud to present the results of their global, pivotal, Phase 3 clinical trial (4WHIM) evaluating the safety and efficacy of mavorixafor in people with WHIM syndrome. Join them today, May 16, 2023, at 4:00 p.m. ET for a company webinar to hear all the details! Don’t miss this chance to learn more about their groundbreaking research in this area.

The PIPE financing saw an impressive line-up of investors joining in including big names like New Enterprise Associates (NEA), Bain Capital Life Sciences, Adage Capital Management, Stonepine Capital Management, LLC, Acorn Bioventures, OrbiMed, Kingdon Capital, and other healthcare specialist investors. With both new and existing investors participating in the financing, the success of the PIPE financing is a testament to the potential of the project.

Piper Sandler and Stifel took the lead in facilitating the offering, with Cantor as co-placement agent and H.C. Wainwright & Co. providing financial advice. This team of experienced professionals brought their expertise to the task, ensuring a successful offering.

With the net proceeds from this transaction, X4 now has the financial resources to fund operations into the fourth quarter of 2024. This includes the potential proceeds from the sale of a priority review voucher, which may be received in the first half of 2024. This provides X4 with the necessary cash and cash equivalents to remain operational and pursue its goals.

X4 is pleased to announce the closing of its PIPE offering, where 42,784,203 shares of common stock (or pre-funded warrants in lieu thereof) were issued at a purchase price of $1.52 (or $1.519 per pre-funded warrant) per share. The purchase price was determined, in part, based on the Nasdaq official closing price. With this offering, X4 looks forward to continued success and growth in the future.

X4 Pharmaceuticals is thrilled to announce that it has raised additional funds to further its mission of advancing clinical development and commercial readiness of its lead candidate, mavorixafor. The funds will also be used to assist with working capital and other corporate objectives. With this additional support, X4 is eager to accelerate progress towards its goal of delivering life-changing therapies to patients and their families worldwide.

X4 is launching an exclusive financing that offers investors the opportunity to purchase securities that have not been registered under the Securities Act of 1933. To ensure their compliance with federal regulations, X4 has agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the shares of common stock and the associated pre-funded warrants. This is a unique opportunity for investors to get involved with X4 before the securities become available to the public.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company that is revolutionizing the way rare diseases of the immune system are treated. Our lead candidate, mavorixafor, is a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy.

We believe mavorixafor has the potential to offer therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency.

Following positive top-line data from our global, pivotal, 4WHIM Phase 3 clinical trial, we are preparing a U.S. regulatory submission seeking approval of mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome.

In addition, we are exploring the potential of mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders, following positive results from a Phase 1b clinical trial of mavorixafor in people with congenital, idiopathic, or cyclic neutropenia. Our team of experts are continuing to explore

Leave a Comment